Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Aredo JV, Hellyer JA, Neal JW, Wakelee HA, et al. J Thorac Oncol 2021;16:1994-1998.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Aredo JV, Hellyer JA, Neal JW, Wakelee HA, et al. Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. J Thorac Oncol 2021;16:1994-1998.
PMID: 34809803